Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments

J Clin Oncol. 2021 Mar 20;39(9):950-955. doi: 10.1200/JCO.20.02768. Epub 2021 Feb 8.
No abstract available

MeSH terms

  • Antineoplastic Agents / economics*
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Cost-Benefit Analysis*
  • Health Care Costs
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / economics*
  • Neoplasms / pathology
  • Prognosis
  • Therapeutic Equivalency
  • Tissue Distribution

Substances

  • Antineoplastic Agents